Twister Biotech, Inc. is focused on research, development and commercialization of MiniVectorsTM - a highly minimized form of supercoiled, circular DNA as small as 250 bp in length. This minimization is achieved by removing all unnecessary bacterial sequences, such as the antibiotic resistance gene and origin of replication from the DNA backbone. The resulting vector can be over 10 times smaller than is possible with traditional plasmids. MiniVectors’ small size allows them to enter cells that are normally difficult or impossible to transfect, providing an ideal platform for gene expression, shRNA or miRNA knockdown, and cell tracking and labeling studies both in vitro and in vivo. A further benefit of the compact, supercoiled structure is that it allows for enhanced physical and biological stability. Finally, the removal of the antibiotic resistance cassette may provide a smoother path toward regulatory approval for MiniVector-based gene therapies.